MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/mri-guided-chemotherapy-duration-yields-favourable-survival-2026a100062k?src=rss
Author :
Publish date : 2026-03-02 12:00:00
Copyright for syndicated content belongs to the linked Source.
